Synthesis and biological evaluation of new N-linked 5-triazolylmethyl oxazolidinones

European Journal of Medicinal Chemistry

Volumn 43, Issue 8, 2008, Pages 1706-1714

  Fan, Houxing ^a   Chen, Yilang ^a   Jiang, Zhiteng ^a   Zhang, Shuhua ^b   Zhong, Dafang ^a   Ji, Ruyun ^a   Yang, Yushe ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b Sichuan Industrial Institute of Antibiotics   (China)

Author keywords

Antibacterial agents; Gram positive organisms; Linezolid; Oxazolidinone

Indexed keywords

5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (2 AMINOBENZYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (2 NITROBENZYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (3 AMINOBENZYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (3 FORMYLBENZYL)PIPERAZIN 1 YL]PHENYL] OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (3 NITROBENZYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (4 AMINOBENZYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (4 FORMYLBENZYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (4 NITROBENZYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (FURAN 2 YLMETHYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (FURAN 3 YLMETHYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (PYRIDIN 2 YLMETHYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (PYRIDIN 3 YLMETHYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (PYRIDIN 4 YLMETHYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (THIOPHEN 2 YLMETHYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 (THIOPHEN 3 YLMETHYL)PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 [(3 METHYLTHIOPHEN 2 YL)METHYL]PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 [(5 BROMOTHIOPHEN 2 YL)METHYL]PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 [(5 CHLOROFURAN 2 YL)METHYL]PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 [(5 METHYLFURAN 2 YL)METHYL]PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 [(5 METHYLTHIOPHEN 2 YL)METHYL]PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; 5 [(1H 1,2,3 TRIAZOL 1 YL)METHYL] 3 [3 FLUORO 4 [4 [(5 NITROFURAN 2 YL)METHYL]PIPERAZIN 1 YL]PHENYL]OXAZOLIDIN 2 ONE; LINEZOLID; OXAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SCREENING; DRUG SYNTHESIS; GRAM POSITIVE BACTERIUM; MOUSE; NONHUMAN;

ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; GRAM-POSITIVE BACTERIA; METHYLATION; MICE; MOLECULAR STRUCTURE; OXAZOLIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 47949120326     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2007.09.010     Document Type: Article

References (20)

1. Pfaller M.A., Jones R.N., Doern G.V., Sader H.S., Kugler K.C., and Beach M.L. Diagn. Microbiol. Infect. Dis. 33 4 (1999) 283-297
2. Abi-Hanna P., Frank A.L., Quinn J.P., Kelkar S., Schreckenberger P.C., Hayden M.K., and Marcinak J.F. Clin. Infect. Dis. 30 3 (2000) 630-631
3. Colligenon P. J. Infect. Dis. 179 6 (1999) 1592
4. Merlino J., Leroi M., Bradbury R., Veal D., and Harbour C. J. Clin. Microbiol. 38 (2000) 2378-2380
5. Cookson B.D. Infect. Control Hosp. Epidemiol. 21 6 (2000) 398-403
6. Clemett D., and Markham A. Drugs 59 4 (2000) 815-827
7. Swaney S.M., Aoki H., Ganoza M.C., and Shinabarger D.L. Antimicrob. Agents Chemother. 42 (1998) 3251-3255 and references cited therein
8. Aoki H., Ke L., Poppe S.M., Poel T.J., Weaver E.A., Gadwood R.C., Thomas R.C., Shinabarger D.L., and Ganoza M.C. Antimicrob. Agents Chemother. 46 (2002) 1080-1085 and references cited therein
9. Tsirodas S., Gold H.S., Sakoulas G., Eliopoulas G.M., Wennerstein C., Venkataraman L., Moellering Jr. R.C., and Ferro M.J. Lancet 358 (2001) 207-208
10. Johnson A.P., Tysall L., Stockdale M.W., Woodford N., Kaufmann M.E., Warner M., Livermoore D.M., Asboth F., and Alleberger F.J. Eur. J. Clin. Microbiol. Infect. Dis. 21 (2002) 751-754
11. Phillips O.A., Udo E.E., Ali A.A.M., and Al-Hassawi N. Bioorg. Med. Chem. 11 1 (2003) 35-41
12. Houxing F., Gang X., Yilang C.H., Zhiteng J., Shuhua Z.H., Yushe Y., and Ruyun J. Eur. J. Med. Chem. 42 8 (2007) 1137-1143
13. Rattan A. Drugs Future 28 (2003) 1070-1077
14. Ednie L.M., Rattan A., Jacobs M.R., and Appelbaum P.C. Antimicrob. Agents Chemother. 47 3 (2003) 1143-1147
15. Brickner S.J., Hutchinson D.K., Barbachyn M.R., Manninen P.R., Ulanowicz D.A., Garmon S.A., Grega K.C., Hendges S.K., Toops D.S., Ford C.W., and Zurenko G.E. J. Med. Chem. 39 3 (1996) 673-679
16. Philips O.A., Udo E.E., Ali A.A.M., and Samuel S.M. Bioorg. Med. Chem. 13 12 (2005) 4113-4123
17. Berry J.M., Watson C.Y., Whish W.J.D., and Threadgill M.D. J. Chem. Soc., Perkin Trans. 1 8 (1977) 1147-1156
18. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grows Aerobically Approved Standards. fourth ed. NCCLS Document M7-M4 (1997), National Committee for Clinical Laboratory Standards, Villanova, PA, USA
19. Bliss C.I. Science 79 (1934) 38-39
20. Bliss C.I. Ann. Appl. Biol. 22 (1935) 134-167